Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy

Maciej Gawęcki; Krzysztof Kiciński; Andrzej Grzybowski

doi:10.1016/j.aopr.2024.01.004

您当前的位置：

首页 >

文章列表页 >

Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy

Full Length Article | 更新时间：2024-05-29

- Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy
- Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy
- 眼科实践与研究新进展 2024年4卷第1期页码：32-38
- 作者机构：
  
  1. Dobry Wzrok Ophthalmological Clinic,Gdansk,Poland,80-822
  2. Department of Ophthalmology, Pomeranian Hospitals in Wejherowo, 84-200, Wejherowo,Poland
  3. ,Poznan,Poland
- 作者简介：
- 基金信息：
- DOI：10.1016/j.aopr.2024.01.004
  中图分类号：
- 纸质出版日期：2024，
扫描看全文
Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy[J]. 眼科实践与研究新进展, 2024,4(1):32-38.

Maciej Gawęcki, Krzysztof Kiciński, Andrzej Grzybowski. Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy[J]. AOPR, 2024,4(1):32-38.
Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy[J]. 眼科实践与研究新进展, 2024,4(1):32-38. DOI： 10.1016/j.aopr.2024.01.004.

Maciej Gawęcki, Krzysztof Kiciński, Andrzej Grzybowski. Crossover to PDT after the unsuccessful micropulse laser treatment of central serous chorioretinopathy[J]. AOPR, 2024,4(1):32-38. DOI： 10.1016/j.aopr.2024.01.004.

摘要

Abstract

PurposeSubthreshold micropulse laser (SML) and photodynamic therapy (PDT) are among the most effective therapeutic modalities applied to central serous chorioretinopathy (CSCR). This study aimed to evaluate the efficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.MethodsThe study included 26 consecutive eyes of 24 patients (21 males and three females) with chronic CSCR. In all cases

a lack of reduction in subretinal fluid (SRF) levels was noted after at least two consecutive SML sessions. The parameters of best corrected visual acuity (BCVA) and spectral domain optical coherence tomography (SD-OCT) were evaluated at baseline and 1

3 and 12 months post-PDT.ResultsThe mean duration of symptoms in the group was 53.81 ± 39.48 months

the mean age of the patients was 49.26 ± 12.91 years

and the mean subfoveal choroidal thickness (SFCT) was 572.11 ± 116.21 mm. Complete resorption of SRF was observed in 21 out of 26 eyes (80.77%) at 1 month and sustained in 18 cases (69.23%) at 12 months. At 12 months

in the sustained group

BCVA improved significantly from 0.39 ± 0.18 to 0.19 ± 0.2 logMAR (

= 0.01)

central subfoveal thickness (CST) reduced from 316.44 ± 75.83 mm to 197.67 ± 22.99 mm (

0.0001)

and SFCT reduced from 579.28 mm to 446.78 mm (

0.0001).ConclusionsPDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment. Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology. Thus

PDT should be considered for patients with prominently increased choroidal thickness.

关键词

Keywords

Photodynamic therapySubthreshold micropulse laserCentral serous chorioretinopathySybretinal fluid

references

1 M. Gawęcki, A. GrzybowskiGanglion cell loss in the course of central serous chorioretinopathy Ophthalmol Ther, 12 (1) (2023 Feb), pp. 517-533, 10.1007/s40123-022-00625-5

2 M. Gawęcki, A. Jaszczuk-Maciejewska, A. Jurska-Jaśko, et al.Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy BMC Ophthalmol, 19 (1) (2019 Jul 25), p. 160, 10.1186/s12886-019-1171-5 PMC6659242

3 M. Gawęcki, A. Grzybowski, M. Pompein-BatkiewiczSignificant visual impairment after short-lasting central serous chorioretinopathy Case Rep Ophthalmol, 13 (3) (2022 Sep 19), pp. 678-685, 10.1159/000525924

4 M. Gawęcki, A. Jaszczuk, A. GrzybowskiShort term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function J Clin Med, 9 (11) (2020 Oct 26), p. 3429, 10.3390/jcm9113429

5 P. Leaver, C. WilliamsArgon laser photocoagulation in the treatment of central serous retinopathy Br J Ophthalmol, 63 (10) (1979 Oct), pp. 674-677, 10.1136/bjo.63.10.674

6 D.M. Robertson, D. IlstrupDirect, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy Am J Ophthalmol, 95 (4) (1983 Apr), pp. 457-466, 10.1016/0002-9394(83)90265-9

7 F. Frankhauser, S. KwasniewskaLasers in Ophthalmology Kugler Publications (2003), p. 269

8 M.U. Işık, M.F.K. Değirmenci, A. SağlıkEfficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy Int J Ophthalmol, 13 (9) (2020 Sep 18), pp. 1404-1410, 10.18240/ijo.2020.09.11

9 M. GawęckiSubthreshold diode micropulse laser combined with intravitreal therapy for macular edema-A systematized review and critical approach J Clin Med, 10 (7) (2021 Mar 31), p. 1394, 10.3390/jcm10071394

10 M. GawęckiMicropulse laser treatment of retinal diseases J Clin Med, 8 (2) (2019 Feb 13), p. 242, 10.3390/jcm8020242

11 J.T. Goté, S.R. Singh, J. ChhablaniComparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy Graefes Arch Clin Exp Ophthalmol, 261 (8) (2023 Aug), pp. 2135-2168, 10.1007/s00417-023-05996-4 Epub 2023 Mar 2

12 T. Zhao, J. Li, Y. Wang, et al.Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China Ann Med, 55 (1) (2023 Dec), Article 2227424, 10.1080/07853890.2023.2227424

13 M. Gawęcki, A. Jaszczuk-Maciejewska, A. Jurska-Jaśko, et al.Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser Graefes Arch Clin Exp Ophthalmol, 255 (12) (2017 Dec), pp. 2299-2306, 10.1007/s00417-017-3783-x Epub 2017 Aug 22

14 P. Scholz, L. Ersoy, C.J. Boon, et al.Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy Ophthalmologica, 234 (4) (2015), pp. 189-194, 10.1159/000439600 Epub 2015 Sep. 26

15 M.G. Altınel, B. Acikalin, H. Gunes, et al.Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy Laser Med Sci, 36 (7) (2021 Sep), pp. 1505-1514, 10.1007/s10103-020-03225-6

16 A. Arsan, H.S. Kanar, A. SonmezVisual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up Eye (Lond)., 32 (4) (2018 Apr), pp. 726-733, 10.1038/eye.2017.293 Epub 2018 Jan 5

17 S. Gorhe, M.K. Chugh, N. Goel, et al.Clinical feature of cystoid macular degeneration in central serous chorioretinopathy Indian J Ophthalmol, 71 (11) (2023 Nov), pp. 3489-3493, 10.4103/IJO.IJO_255_23

18 M. Battaglia Parodi, A. Arrigo, P. Iacono, et al.Central serous chorioretinopathy: treatment with laser Pharmaceuticals, 13 (11) (2020 Nov 2), p. 359, 10.3390/ph13110359

19 J.M. Ruiz-Moreno, F.L. Lugo, F. Armadá, et al.Photodynamic therapy for chronic central serous chorioretinopathy Acta Ophthalmol, 88 (3) (2010 May), pp. 371-376, 10.1111/j.1755-3768.2008.01408.x Epub 2009 Nov 27

20 P. Iacono, S. Da Pozzo, M. Varano, et al.Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: a review of data and efficacy Pharmaceuticals, 13 (11) (2020 Oct 29), p. 349, 10.3390/ph13110349

21 M.P. Ruiz-Del-Tiempo, P. Calvo, A. Ferreras, et al.Anatomical retinal changes after photodynamic therapy in chronic central serous chorioretinopathy J Ophthalmol, 2018 (2018 Feb 6), Article 4081874, 10.1155/2018/4081874

22 F.H. Lai, D.S. Ng, M. Bakthavatsalam, et al.A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy Am J Ophthalmol, 170 (2016 Oct), pp. 91-99, 10.1016/j.ajo.2016.07.026 Epub 2016 Aug 9

23 C.C. Tseng, S.N. ChenLong-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy Br J Ophthalmol, 99 (8) (2015 Aug), pp. 1070-1077, 10.1136/bjophthalmol-2014-305353 Epub 2015 Feb 13

24 I. Flores-Moreno, G. Arcos-Villegas, M. Sastre, et al.Changes in choriocapillaris, sattler, and haller layer thicknesses in central serous chorioretinopathy after half-fluence photodynamic therapy Retina, 40 (12) (2020 Dec), pp. 2373-2378, 10.1097/IAE.0000000000002764

25 C. Alovisi, F.C. Piccolino, M. Nassisi, et al.Choroidal structure after half-dose photodynamic therapy in chronic central serous chorioretinopathy J Clin Med, 9 (9) (2020 Aug 24), p. 2734, 10.3390/jcm9092734

26 C. Alovisi, F.C. Piccolino, M. Nassisi, et al.Choroidal structure after half-dose photodynamic therapy in chronic central serous chorioretinopathy J Clin Med, 9 (9) (2020 Aug 24), p. 2734, 10.3390/jcm9092734

27 J.E.E. Keunen, M. Battaglia-Parodi, S. Vujosevic, et al.International retinal laser society guidelines for subthreshold laser treatment Transl Vis Sci Technol, 9 (9) (2020 Aug 7), p. 15, 10.1167/tvst.9.9

28 J. Chhablani, F.B. Cohen, Central Serous Chorioretinopathy International GroupMultimodal imaging-based central serous chorioretinopathy classification Ophthalmol Retina, 4 (11) (2020 Nov), pp. 1043-1046, 10.1016/j.oret.2020.07.026

29 M. Battaglia Parodi, S. Da Pozzo, G. RavalicoPhotodynamic therapy in chronic central serous chorioretinopathy Retina, 23 (2) (2003 Apr), pp. 235-237, 10.1097/00006982-200304000-00016

30 W.M. Chan, D.S. Lam, T.Y. Lai, et al.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level Br J Ophthalmol, 87 (12) (2003 Dec), pp. 1453-1458, 10.1136/bjo.87.12.1453

31 L.A. Yannuzzi, J.S. Slakter, N.E. Gross, et al.Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study Retina, 23 (2003), pp. 288-298, 10.1097/00006982-200306000-00002

32 C. Hara, K. Maruyama, T. Wakabayashi, et al.Choroidal vessel and stromal volumetric analysis after photodynamic therapy or focal laser for central serous chorioretinopathy Transl Vis Sci Technol, 12 (11) (2023 Nov 1), p. 26, 10.1167/tvst.12.11.26

33 J.K. Luttrull, C. Sramek, D. Palanker, et al.Long-term safety, high-resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema Retina, 32 (2) (2012 Feb), pp. 375-386, 10.1097/IAE.0b013e3182206f6c

34 I. KozakEditorial to: the effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy Graefes Arch Clin Exp Ophthalmol (2023 Dec 1), 10.1007/s00417-023-06316-6

35 T.J. van Rijssen, E.H.C. van Dijk, P. Scholz, et al.Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial Am J Ophthalmol, 216 (2020 Aug), pp. 80-89, 10.1016/j.ajo.2020.04.007 Epub 2020 Apr 11

36 E.H.C. van Dijk, S. Fauser, M.B. Breukink, et al.Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial Ophthalmology, 125 (10) (2018 Oct), pp. 1547-1555, 10.1016/j.ophtha.2018.04.021 Epub 2018 Jun 14

37 X. Zhang, C.Z.F. Lim, J. Chhablani, et al.Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies Eye Vis (Lond)., 10 (1) (2023 Jul 11), p. 33, 10.1186/s40662-023-00349-y

38 E.H.C. van Dijk, T.J. van Rijssen, Y. Subhi, et al.Photodynamic therapy for chorioretinal diseases: a practical approach Ophthalmol Ther, 9 (2) (2020 Jun), pp. 329-342, 10.1007/s40123-020-00250-0 Epub 2020 Apr 11

39 L. Toto, R. D'Aloisio, C. De Nicola, et al.Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy Sci Rep, 12 (1) (2022 Mar 18), p. 4727, 10.1038/s41598-022-08764-2

40 M.G. Ersoz, S. Arf, M. Hocaoglu, et al.Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients Br J Ophthalmol, 103 (6) (2019 Jun), pp. 725-729, 10.1136/bjophthalmol-2018-312431 Epub 2018 Jul 12

41 N.A. Dhirani, Y. Yang, S. SomaniLong-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy Clin Ophthalmol, 11 (2017 Dec 6), pp. 2145-2149, 10.2147/OPTH.S151933

42 S.H. Lee, J. Lee, M. Kim, et al.The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy Graefes Arch Clin Exp Ophthalmol (2023 Nov 27), 10.1007/s00417-023-06315-7 Epub ahead of print

43 A. Arrigo, E. Aragona, A. Bordato, et al.Acute central serous chorioretinopathy subtypes as assessed by multimodal imaging Transl Vis Sci Technol, 10 (13) (2021 Nov 1), p. 6, 10.1167/tvst.10.13.6

44 M. Gawęcki, A. Jaszczuk-Maciejewska, A. Jurska-Jaśko, et al.Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset J Clin Med, 8 (9) (2019 Sep 6), p. 1398, 10.3390/jcm8091398

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据